A review highlights IL-6 trans-signalling as a possible target in ALS
Original source
Interleukin-6 trans-signalling as a selectively targetable driver of neurodegeneration. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
A review describes interleukin-6 (IL-6) trans-signalling as a possible driver of chronic inflammation and neurodegeneration in amyotrophic lateral sclerosis (ALS). It examines whether selectively blocking this signalling route could reduce harmful inflammation while preserving potentially beneficial IL-6 effects.
Why this matters
This may guide future ALS research into more selective anti-inflammatory treatments. The work is a review of emerging evidence and does not demonstrate a benefit for people with ALS or change current treatment.
Limitations and context
This is a journal review, not a clinical trial or new treatment study. It discusses emerging evidence and identifies knowledge gaps, so the proposed approach still needs to be tested in relevant disease models and people with ALS.